Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The effect of glucagon-like peptide-1 receptor agonists on outcomes in knee osteoarthritis among persons with obesity has not been well studied. METHODS We conducted a 68-week, double-blind, randomized, placebo-controlled trial at 61 sites in 11 countries. Participants with obesity (a body-mass index [BMI; the weight in kilograms divided by the square of the height in meters] of ≥30) and a clinical and radiologic diagnosis of moderate knee osteoarthritis with at least moderate pain were randomly assigned, in a 2:1 ratio, to receive once-weekly subcutaneous semaglutide (2.4 mg) or placebo, in addition to counseling on physical activity and a reduced-calorie diet. The primary end points were the percentage change in body weight and the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score (on a scale of 0 to 100, with higher scores reflecting worse outcomes) from baseline to week 68. A key confirmatory secondary end point was the physical-function score on the 36-Item Short Form Health Survey (SF-36), version 2 (on a scale of 0 to 100, with higher scores indicating greater well-being). RESULTS A total of 407 participants were enrolled. The mean age was 56 years, the mean BMI 40.3, and the mean WOMAC pain score 70.9. A total of 81.6% of the participants were women. The mean change in body weight from baseline to week 68 was -13…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Semaglutide (2•4 mg/week) has been shown to cause symptomatic improvement related to moderate knee osteoarthritis as well as bodyweight reduction.89”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [89]
In the citing paper
“In a 68-week clinical trial involving individuals with obesity and knee osteoarthritis with moderate to severe pain (STEP-9), semaglutide treatment led to a greater reduction in the Western Ontario and McMaster Universities Osteoarthritis Index score (–41.7 points) as compared with placebo (–27.5 points) (88).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [88]
In the citing paper
“While the contribution of weight loss remains unclear, this study, alongside emerging preclinical data from rodent models, suggests that GLP-1 medicines may offer efficacy in inflammation-driven diseases independent of the amelioration of metabolic dysfunction.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [88]
In the citing paper
“In the STEP-9 trial, use of semaglutide led to greater weight loss and improvements in knee pain and physical function compared to placebo in patients with obesity and moderate-to-severe osteoarthritis-related symptoms.45”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [45]
In the citing paper
“In the STEP 9 trial involving adults with obesity and knee osteoarthritis, semaglutide resulted in significantly greater weight loss (− 13.7% vs. −3.2%), pain reduction (WOMAC − 41.7 vs. −27.5 points), and improvement in physical function (SF-36 + 12.0 vs. +6.5 points) compared to placebo (all P < 0.001) at 68 weeks, with a similar rate of serious adverse events [63].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [63]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Altman, R., Asch, E., Bloch, D., Bole, G., Borenstein, D., Brandt, K., Christy, W., Cooke, T. D., Greenwald, R., Hochberg, M., et al. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780290816 · Cited by 6,777
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationHunter, D. J., & Bierma-Zeinstra, S. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30417-9 · Cited by 4,795
OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis
Bannuru, R. R., Osani, M. C., Vaysbrot, E. E., Arden, N. K., Bennell, K., Bierma-Zeinstra, S. M. A., Kraus, V. B., Lohmander, L. S., Abbott, J. H., Bhandari, M., et al. (2019) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2019.06.011 · Cited by 3,542
Kolasinski, S. L., Neogi, T., Hochberg, M. C., Oatis, C., Guyatt, G., Block, J., Callahan, L., Copenhaver, C., Dodge, C., Felson, D., et al. (2020) · Arthritis Care & Research · doi:10.1002/acr.24131 · Cited by 2,516
Classifications in Brief: Kellgren-Lawrence Classification of Osteoarthritis
Kohn, M. D., Sassoon, A. A., & Fernando, N. D. (2016) · Clinical Orthopaedics & Related Research · doi:10.1007/s11999-016-4732-4 · Cited by 1,459
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Self-citationDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 101–200 of 438
Hall, M., Hinman, R. S., Knox, G., Spiers, L., McManus, F. J., Silva, A. P. D., Sumithran, P., Harris, A., Murphy, N. J., Cicuttini, F., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-00045 · Cited by 9
Wu, R., Xing, B., Zhou, Z., Yu, L., & Wang, H. (2025) · European journal of medical research · doi:10.1186/s40001-025-03124-y · Cited by 9
“However, no significant effects were observed for other CV outcomes, including angina unstable (RR 0.87, 95% CI 0.72– 1.06; I 2 0%, 4 studies [15, 19–21]), coronary artery disease (RR 0.76, 95% CI 0.57–1.01; I 2 0%, 4 studies [15, 18–20]), cardiac failure congestive (RR 0.80, 95% CI 0.50–1.28; I 2…”
InfluentialAntiobesity medications in rheumatology. Quo vadis?
Kyriazi, N., Vassilakis, K. D., Bakiri, A., Iliopoulos, A., & Fragoulis, G. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.08.013 · Cited by 8
Wu, X., Li, S., & Wu, M. (2025) · Journal of Pain Research · doi:10.2147/jpr.s543346 · Cited by 14
Tseng, P., Zeng, B., Hsu, C.-W., Sun, C., Suen, M., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01750-x · Cited by 10
Zhang, X., Chi, R., Xu, J., Meng, C., Wang, Z., Ruo, W., Xin, F., Xu, T., Guo, F., Wang, G., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.116010 · Cited by 7
Al-Dahi, W. A., Alenezi, A., Alessa, T., Alhamdan, R., Al-Humood, K., Alqallaf, A., AlOtaibi, T. M., AlRajab, H., Alshammari, A. M., Alyousef, A., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01838-0 · Cited by 9
Advances in heterogeneity and classification of osteoarthritis
Huang, T., 舒建雄, Wu, Z. Z., Li, Z. A., Tuan, R. S., Ding, C., & Lu, Y. (2026) · Bone Research · doi:10.1038/s41413-026-00549-x · Cited by 10
“150 The results demonstrate that semaglutide signi fi cantly reduced body weight and pain related to knee OA compared to placebo.”
Beyond weight: Exploring the nexus between obesity and osteoarthritis
Ningtyas, M. C., Ansharullah, B. A., Sutanto, H., & Prajitno, J. H. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102526 · Cited by 9
Chen, H., Si, L., Hunter, D. J., Zhang, L., Chen, Z., Wang, X., Duong, V., Zhou, Z., Cao, P., Cen, H., et al. (2025) · Arthritis Care & Research · doi:10.1002/acr.25617 · Cited by 6
Pharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 33
Silverii, G. A., Monami, M., Rotella, F., Luca, M. D., Viozzi, T., Barazzoni, R., Buscemi, S., Busetto, L., Sbraccia, P., & Mannucci, E. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70202 · Cited by 6
“…(three with RYGB, 18 – 20 one with ESG 21 and DJBL, 22 respectively), one on Orlistat, 23 two with Phentermine/Topiramate, 24,25 three Naltrexone/Bupropion, 26 – 28 five Tirzepatide, 29 – 33 and 14 with GLP1-RAs (six with Liraglutide 34 – 39 and eight with Semaglutide, 40 – 47 respectively).”
Yang, H., Zeng, M., Fan, T., Chen, H., Fang, X., Li, Z. A., Wang, X., Hunter, D. J., Ding, C., & Zhu, Z. (2025) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.02.004 · Cited by 10
Elangovan, H., Gunton, J. E., Zheng, M., Fan, J.-G., Goh, G. B., Grønbæk, H., & George, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10795-6 · Cited by 7
“Multiple phase 2 and 3 trials support the use of incretin drugs in chronic kidney disease (CKD) [14], osteoarthritis [15], obstructive sleep apnea (OSA) [16] and even in early Parkinson’s disease [17], demonstrating the pleiotropic benefits of these agents in preventing chronic disease progression…”
InfluentialIndividualized Management of Osteoarthritis: The Role of Pharmacogenomics to Optimize Pain Therapy
Sturgeon, I. M., & Roman, Y. M. (2025) · Future Pharmacology · doi:10.3390/futurepharmacol5020030 · Cited by 6
Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide
Bernardi, J. C., Cavalcante, D. V. S., Huntermann, R., Molinari, M. E., Zanon, L. Z., Khater, J., Gomez, V. A., & Fischer‐Bacca, C. O. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70192 · Cited by 5
Kreutzinger, V., Ziegeler, K., Joseph, G. B., Lynch, J. A., Akkaya, Z., Lane, N. E., McCulloch, C. E., Nevitt, M. C., & Link, T. M. (2025) · Osteoarthritis and Cartilage Open · doi:10.1016/j.ocarto.2025.100653 · Cited by 5
“Our results carry potential clinical significance in light of the observation that obese OA patients taking GLP-1 agonists like semaglutide experience a reduction in knee pain [25], which is associated with synovitis on MRI [26].”
Alqatari, S. G., Alwaheed, A., Hasan, M. A., Argan, R. A., Alabdullah, M. M., & Shubbar, M. D. A. (2025) · Medicina · doi:10.3390/medicina61071292 · Cited by 11
“…kidney disease risk, slows eGFR decline, improves albuminuria, reduces CV events and mortality [16] Improves osteoarthritic pain and function [23] Reduces liver fat content [48] Reduces all-cause mortality [16] ~15% by week 68 [19] GLP-1 receptor agonist Orforglipron Reduces HbA1c level [52]…”
Weight management treatment in obesity
Rubio, M. Á., & Carreiro, S. M. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107152 · Cited by 7
Not Just Neurons: Pain Is Orchestrated in Partnership with Many Non-neuronal Cells
Smith, E. S. J., Burton, M. D., Heegaard, A., & Stucky, C. L. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.1309-25.2025 · Cited by 7
Pharmacological Management of Diabesity: Current and Emerging Therapies
Galasso, M., Caporusso, M., Volatile, A., Verde, L., Esposito, K., Giorgino, F., Perrini, S., Colao, A., Barrea, L., & Muscogiuri, G. (2026) · Current Obesity Reports · doi:10.1007/s13679-025-00681-5 · Cited by 6
“%) with semaglu - tide, highlighting its potential benefit in weight-sensitive comorbid conditions [42].”
Haberman, R. H., Rice, A. L., Chen, K., Scher, U., Thib, S., Scher, J. U., & Eder, L. (2026) · Arthritis & Rheumatology · doi:10.1002/art.70170 · Cited by 8
Zhou, L., He, S., Li, C., Ding, C., Tuan, R. S., & Li, Z. A. (2025) · The Innovation Medicine · doi:10.59717/j.xinn-med.2025.100110 · Cited by 5
The Goldilocks for chronic weight management—Balancing quantity with quality of weight loss
Henriksen, K., Chakravarthy, M. V., Bager, C. L., Larsen, A. T., Mohamed, K. E., & Karsdal, M. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16379 · Cited by 4
Osteoimmunology and aging — a frontier to explore
Ille, M., Adamopoulos, I. E., Fain, M. J., & Nikolich‐Žugich, J. (2025) · GeroScience · doi:10.1007/s11357-025-01744-0 · Cited by 6
Obesity and Comorbidity Management in Psoriatic Arthritis
Maharaj, A. B., Eder, L., & Ogdie, A. (2025) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2025.07.001 · Cited by 4
Physical Frailty and Sarcopenia in Liver Transplantation: How Should They Be Assessed and Addressed?
Ngonadi, C., Hopkins, L., Williams, F. R., & Armstrong, M. J. (2025) · Transplantation · doi:10.1097/tp.0000000000005519 · Cited by 4
Ursini, F., Ciaffi, J., & Caporali, R. F. (2025) · RMD Open · doi:10.1136/rmdopen-2025-006025 · Cited by 4
“5 However, extensive weight management literature offers substantial evidence supporting the effectiveness of GLP-1 RAs for individuals in this BMI category.”
InfluentialMobasheri, A., Henriques, J., & Collins, J. E. (2025) · Osteoarthritis Imaging · doi:10.1016/j.ostima.2025.100374 · Cited by 5
“…could potentially also have beneficial impacts on the BM microenvironmental niche in subchondral bone of obese individuals with OA in addition to their known effects on bone metabolism [113 – 115] and the recently reported pain and function benefits in persons with obesity and knee OA [116].”
Barazzoni, R., Monami, M., Buscemi, S., Busetto, L., Luca, M. D., Navarra, G., Ragghianti, B., Silverii, G. A., Belluzzi, A., Mannucci, E., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70204 · Cited by 7
Elangovan, H., Loomba, R. S., Muthiah, M. D., Schattenberg, J. M., Zheng, M., Noureddin, M., Mantzoros, C. S., & George, J. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0857 · Cited by 5
The role of GLP-1 receptor in pain disorders and its pharmacological properties
Jing, F., Zeng, Y., Yu, Q.-L., & Fu, C. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178345 · Cited by 6
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101445 · Cited by 12
“In the STEP 9 [83] trial, semaglutide 2.4 mg administered once weekly resulted in significant improvements in knee pain, function, and stiffness, as well as weight loss, in individuals with obesity and symptomatic knee osteoarthritis.”
InfluentialThe effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
Zeng, B.-S., Chen, J.-J., Hsu, C.-W., Hung, C.-M., Zeng, B., Suen, M., Yang, W.-C., Wang, H.-Y., Shiue, Y.-L., Su, K.-P., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.014 · Cited by 8
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70167 · Cited by 5
Albor, C., Anyiam, O., Boyle, L., Makaronidis, J., Tan, R. J. L., Iftikhar, S., Burzić, A., Lajeunesse‐Trempe, F., Stanley, M., Bhatti, A. I., et al. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00707-6 · Cited by 5
Beyond weight loss: multisystem benefits of obesity medications
Savas, M., Kuckuck, S., Boon, M. R., & van Rossum, E. F. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00100-2 · Cited by 5
Carter, V., Desverreaux, E., Amin, I., Fogarty, A. E. C., Hussain, N., D'Souza, R. S., & Karri, J. V. (2026) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2026-107658 · Cited by 6
“12 Complementing these clinical findings, emerging mechanistic studies suggest that semaglutide may exert chondroprotective and anti-inflammatory effects, independent of weight loss, through activation of GLP-1 R–AMPK signaling and metabolic reprogramming within cartilage tissue.”
Novel therapeutic strategies for osteoarthritis: from mechanistic insights to precision medicine
Umar, M., Wang, Z., Li, J., Li, Z., Li, G., Tong, L., & Chen, D. (2026) · Bone Research · doi:10.1038/s41413-026-00540-6 · Cited by 6
“41,107 Hyaluronic acid .”
Conforti, A., Lucchetti, L., Ciampa, F., Bonifacio, M., Musorrofiti, M. G., Cipolloni, V., & Messina, F. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15155876 · Cited by 4
Mulcahy, J., DeLaRosby, A., & Norwood, T. (2025) · Physical Therapy · doi:10.1093/ptj/pzaf061 · Cited by 8
Advancements in understanding the role of obesity in osteoarthritis
Goh, I. Y., Ghosh, U., & Harasymowicz, N. S. (2025) · Connective Tissue Research · doi:10.1080/03008207.2025.2533330 · Cited by 4
“Additionally, participants in the Semaglutide group experienced a more substantial improvement in physical function score than those in the placebo group 28 .”
Singh, M. P., Yadav, R., & Singh, A. D. (2025) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-02000-4 · Cited by 4
“According to the RoB tool, both RCTs were assessed to have a low risk of bias [22, 23] ( Fig.”
Beyond weight loss: GLP-1 emerges as a disease-modifying signal in osteoarthritis
Berenbaum, F. (2025) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2025.06.011 · Cited by 5
Lisco, G., Tullio, A. D., Zupo, R., Prete, M., Piazzolla, G., Racanelli, V., & Triggiani, V. (2025) · Immunologic Research · doi:10.1007/s12026-025-09655-0 · Cited by 4
Larsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3
Hip and Knee Arthroplasty in Patients with Obesity
Koh, C. K., Garceau, S. P., Grammatopoulos, G. A., & Beaulé, P. E. (2025) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.25.00131 · Cited by 3
Li, Y., Yang, L., Li, F., Fu, J., Zhao, W., Wu, X., Guo, J., & Chen, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1627691 · Cited by 4
Yen, F., Wang, S., Hwu, C., Huang, C., Chang, R., Hsu, C.-C., & Wei, J. C.-C. (2025) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103493 · Cited by 7
Jeon, M., Hong, B., Ko, H. Y., Song, H. J., Kwak, S. H., Kim, J. H., & Shin, J. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113091 · Cited by 4
The important role of comorbidities in the management of obesity
Barenbaum, S. R., Tchang, B. G., & Aronne, L. J. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag012 · Cited by 5
Heijman, M. W. J., Hartog, M., van den Ende, C. H. M., Popa, C. D., & van den Bemt, B. J. F. (2026) · Drugs · doi:10.1007/s40265-025-02278-7 · Cited by 4
“This procedure was applied to a high-quality dataset with as few duplicates as possible and included a set of key papers meeting the eligibility criteria that were determined by consensus of the research team [18–25].”
Bariatric Surgery in the Era of GLP1RA: A Narrative Review
Muhundan, M., & Dash, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03494-7 · Cited by 2
“Improvements in knee pain related to osteoarthritis were seen in patients treated with subcutaneous sema-glutide [70].”
Zhang, H., Liu, Y., Zhang, S., Wang, Z., Zhang, X., Zhang, Y., Zhang, J., Liang, S., Li, C., Su, M., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04261-0 · Cited by 7
“It should also be noted that in recent large-scale clinical trials there were signs of good treatment potential for GLP-1RAs in osteoarthritis (OA) [13, 14].”
GLP-1 medications for weight-loss: a triumph of marketing over patient care
Chastain, R., Meadows, A., & Adams, L. (2026) · Fat Studies · doi:10.1080/21604851.2026.2646492 · Cited by 6
The gut–joint axis in osteoarthritis
Wei, J. H., Zhang, Y., Xie, C., Lei, G., & Zeng, C. (2026) · Nature Reviews Rheumatology · doi:10.1038/s41584-026-01378-2 · Cited by 6
“By contrast, a multi-centre RCT involving 407 people with obesity and moderate-to-severe knee OA demonstrated that semaglutide reduced body weight, alleviated OA-related pain and improved physical function 128 .”
Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map
Jensterle, M., & Janež, A. (2026) · Drugs · doi:10.1007/s40265-026-02325-x · Cited by 6
Lin, J., Luo, M., Tang, H., Lu, K., Mou, Y., Jiang, Q., Yuan, X., Deng, Z., Xu, W., Nie, M., et al. (2026) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2026.101166 · Cited by 4
“The recent STEP-9 clinical trial demonstrated that semaglutide mediated approximately 13.7% weight loss in obese patients with knee OA, while significantly improving joint pain and function; the study primarily attributed the observed joint benefits to weight reduction [16].”
InfluentialXu, K., Li, J., Wang, G., Lin, J., & Li, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1825725 · Cited by 3
“…and knee OA is especially informative in this regard, because it showed that metabolic intervention can signi fi cantly reduce body weight and improve OA-related pain, thereby strengthening the clinical relevance of the metabolic phenotype without proving direct reversal of cartilage pathology (73).”
InfluentialOsteoarthritis: Epidemiology, Diagnosis, and Treatment
Ru, Q., Yuan, D. Z., Jiang, S., Zhao, X., Liu, X., Li, Y., Liu, S., & Wu, Y. (2026) · MedComm · doi:10.1002/mco2.70834 · Cited by 3
Melman, A., Menz, F., Needs, C., de Campos, T. F., Marabani, M., Bostock, K., Dick, R., Hayes, S., Zadro, J. R., Machado, G. C., et al. (2025) · Musculoskeletal Care · doi:10.1002/msc.70174 · Cited by 3
Ciaffi, J., Ursini, F., Peta, G., Zaffagnini, S., Muccioli, G. M. M., & Facchini, G. (2025) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2025.2547454 · Cited by 3
Precision weight management in people with knee osteoarthritis and overweight or obesity
Yuan, S., & Hunter, D. J. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01209-2 · Cited by 3
Costa, G. P. A., Suh, R., Nunes, J. C., Pittman, B. P., Sofuoglu, M., Petrakis, I. L., & Aquino, J. P. D. (2025) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70108 · Cited by 3
Fármacos basados en GLP-1: mecanismos implicados en el tratamiento de la obesidad
Salvador, J. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107035 · Cited by 13
Recent developments in pharmacologic therapy of synovitis in osteoarthritis
Berenbaum, F. (2025) · Skeletal Radiology · doi:10.1007/s00256-025-04976-5 · Cited by 2
“Subcutaneous semaglutide has been shown to reduce pain from knee OA, along with significant weight loss [50].”
Riley, T. R., Wipfler, K., Wysham, K. D., Ranganath, V. K., George, M., Michaud, K. D., & Baker, J. F. (2025) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2025.152783 · Cited by 2
Dalpiaz, H., Masi, S., Piludu, S., Agnoletti, D., Piani, F., Fiorini, G., & Borghi, C. (2025) · Heart · doi:10.1136/heartjnl-2024-324847 · Cited by 4
“For instance, in obese patients, GLP-1RA might combine the benefits of effective cardioprotection with those of a substantial weight reduction, potentially attenuating the symptom burden due to other comorbidities (eg, osteoarthritis 50 or obstructive sleep apnoea 51 ).”
Lingow, S. E., Carris, N. W., Clements, J. N., Courtney, L. A., Lennon, A., Sherrill, C. H., & Dril, E. V. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70111 · Cited by 5
Belančić, A. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70130 · Cited by 3
Update on clinical heart failure trials
Hoevelmann, J., Tokcan, M., Kulenthiran, S., Abdin, A., Viljoen, C. A., & Böhm, M. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02784-4 · Cited by 2
Paisan, M., Papadopoulos, K. I., Papadopoulou, A., Prasongchean, W., & Wattanaarsakit, P. (2025) · World Journal of Orthopedics · doi:10.5312/wjo.v16.i12.110992 · Cited by 4
Saeed, Z. I., & Apovian, C. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01369-w · Cited by 2
Understanding the Inflammatory Aspect of Osteoarthritis: Lessons from Immune Checkpoint Inhibitors
Portnoy, D. M., Paiola, M., Tymm, C. C., WINCHESTER, R. J., Mor, A., & Gartshteyn, Y. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020658 · Cited by 3
“In a recent Phase 3 clinical trial that enrolled patients with obesity and knee osteoarthritis, treatment with the once-weekly GLP-1 agonist semaglutide resulted in more significant reductions in body weight and pain related to knee OA compared to placebo [111].”
Chen, H., Dang, Q., Shi, Y., Hunter, D. J., Wang, X., Yang, H., Si, L., Duong, V., Zhang, M., Wang, Z., et al. (2026) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.70548 · Cited by 2
Bay‐Jensen, A., Mohamed, K., Frederiksen, P., Bihlet, A. R., Thudium, C. S., Henriksen, K., & Karsdal, M. (2026) · BMC Rheumatology · doi:10.1186/s41927-026-00628-w · Cited by 2
“The bone resorption marker sCTX-I increased 1.58-fold [1.38, 1.80] and 1.36-fold [1.26, 1.46] in the weight loss and stable weight groups, respectively, in contrast to the weight gain group, in which it did not change (Fig.”
InfluentialKo, D., Kim, D. H., Tan, F. X. N., Ho, G. J. K., Chandra, R., Xuan, Z. Z., Tham, E. K. J., Tang, N. S. Y., Yang, H. S., Koh, J. W. H., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102614 · Cited by 3
Chan, P. Y., Yuan, S., & Hunter, D. J. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2649611 · Cited by 2
“…2.4 mg in people with obesity and symptomatic knee OA produced clinically meaningful improvements in knee pain and function alongside substantial weight loss, illustrating a dual musculoskeletal-metabolic benefit and a pragmatic pathway to improve OA symptoms while reducing CMD risk factors [105].”
InfluentialSemaglutide for Alzheimer's disease after evoke and evoke+
Schneider, L. S. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00514-3 · Cited by 3
GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs
Vienghirun, J., Sawangjit, R., Suttiruksa, S., Chaiyakunapruk, N., Jinathongthai, P., Khunti, K., & Lee, S. W. H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70698 · Cited by 4
Chen, Y., Kraus, V. B., Chang, Y., Lin, T.-M., Lee, H.-Y., Chang, C., Kuo, T., Chen, J.-H., & Chang, C. (2026) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x261434279 · Cited by 3
“26,27 Consistent with this hypothesis, the Shanghai Osteoarthritis Cohort reported improved Western Ontario and McMaster Universities Osteoarthritis Index scores, attenuated cartilage damage, and fewer TKR surgeries among GLP-1 RA users with T2DM.”
Yang, W., Hao, C., Wang, N., Xie, J., Zhou, B., Yang, Z., Zheng, A., Wei, J., Li, C., Xie, C., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2661854 · Cited by 3
“145 Concerns over sarcopenic obesity with GLP-1RAs use have prompted investigation into combination therapies; 247,248 the phase 2 Bimagrumab and Semaglutide for Body Composition in Obesity (BELIEVE) trial showed that adding bimagrumab to semaglutide enhanced fat loss while increasing lean mass,…”
Çiftçi, E., Eberlein, S. C., Grad, S., Alini, M., Berenbaum, F., & Li, Z. (2026) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2026.04.018 · Cited by 4
Teli, B., Somani, S., Arya, V., Rajput, P. J., Kahale, P., Bharmal, V. S., Shah, S., Patel, V., Ahuja, A., & PATANGE, S. A. (2026) · Cureus · doi:10.7759/cureus.108999 · Cited by 2
“Among individuals with obesity and moderate-to-severe knee osteoarthritis pain, once-weekly injectable semaglutide 2.4 mg produced significantly greater reductions in osteoarthritis-related pain score by 41.7 points versus 27.5 points with placebo [36].”
InfluentialMeza, A. D. V., Nocek, M. J., Mitchell, B. C., Lizarraga, M. A., DeFoor, M. T., Ruzbarsky, J. J., Huard, J., & Philippon, M. J. (2026) · JBJS Reviews · doi:10.2106/jbjs.rvw.26.00027 · Cited by 3
Li, J., Cao, B., Yu, S., Li, C., Xue, M., xie, Q., Luo, C., Duan, C., Li, Z., & Jin, C. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s610406 · Cited by 4
Hu, H., Yin, H., Liu, Y.-W., Wang, Z., & Xie, H. (2026) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2026.101139 · Cited by 2
“The STEP-9 trial and several cohort studies have shown that patients receiving GLP-1 RA treatment not only experience significant relief in joint pain but also have a markedly lower risk of total knee replacement (TKR) [265,266,273].”
Cardiovascular Risk Reduction With GLP-1 RA Drugs
Pigeyre, M., & Gerstein, H. C. (2026) · Circulation · doi:10.1161/circulationaha.126.079319 · Cited by 4
Chen, H.-Y., Wu, J., Chu, Y.-H., Chen, T.-W., & Huang, C. (2026) · Osteoporosis International · doi:10.1007/s00198-026-08134-y · Cited by 5
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
Jastreboff, A. M., Kaplan, L. M., Davies, M. J., Wilding, J. P. H., Ahmad, N. N., Murray, M. H., Du, Y., Makarova, N., Giblin, K. A., Schloot, N. C., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2604169 · Cited by 9
Rheumatology: What You May Have Missed in 2024
Blau, B. J., & Mandl, L. A. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-00927 · Cited by 2
Effects of Weight-lowering Medications in People With Obesity and Rheumatic Diseases
Karacabeyli, D., & Lacaille, D. V. (2025) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-025-00232-y · Cited by 3
“These between-group differences met thresholds for both statistical significance and clinical importance [ 47 , 50].”
InfluentialLisco, G., Jo, H.-G., & Colaianni, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1540942 · Cited by 4
Khan, M. A. S., Ali, M. A., Atieh, F. M., Ali, S. M., El-Hagrasy, A. M. A., Khan, H. N., & Butt, A. J. (2025) · Cureus · doi:10.7759/cureus.83968 · Cited by 1
Burns, R. B., Skorupa, T., Abdeen, A. R., & Kanjee, Z. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-01411 · Cited by 2
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2582-5787 · Cited by 1
Obesity, Weight Loss, and Knee Osteoarthritis: The Role of Glucagon-Like Peptide-1 Receptor Agonists
Felson, D. T., & Stokes, A. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-03113 · Cited by 1
Abdelnabi, M. H., Chaisrimaneepan, N., Castillo‐Rodriguez, C., Eshak, N., Sullivan, M. M., Ibrahim, R., Pham, H. N., Farina, J., Ayoub, C., Nagaraja, V., et al. (2025) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-025-01124-z · Cited by 1
“The STEP 9 trial demonstrated that semaglutide use in obese non-diabetic patients with moderate-to-severe knee OA not only reduced body weight but also pain and analgesic use and improved physical function [47].”
Jones, G. (2025) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2025.102102 · Cited by 1
Application of saphenous nerve infrapatellar branch protection technique in total knee arthroplasty
Mao, Z.-Q., Li, K., Zhang, Z., Li, T., Lu, J., Fan, M., & Chu, X. (2025) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-025-09099-5 · Cited by 1
Metadata
- Authors
- Bliddal, H., Bays, H., Czernichow, S., Uddén Hemmingsson, J., Hjelmesæth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Vélez Sánchez, P., Wharton, S., Wizert, A., & Kristensen, L. E.
- Affiliations
- University of Louisville (US)
- From the Parker Institute, Copenhagen University Hospital at Bispebjerg and Frederiksberg, Copenhagen (H. Bliddal, L.E.K.), and Novo Nordisk, Søborg (T.H.M., A.K., J.S.N., A.W.) — both in Denmark; Louisville Metabolic and Atherosclerosis Research Center, University of Louisville School of Medicine, Louisville, KY (H. Bays); the Department of Nutrition, Hôpital Européen Georges Pompidou, Assistance Publique–Hôpitaux de Paris, Université Paris Cité, Paris (S.C.); the Obesity Department, Capio St. Göran’s Hospital, and Medical Department at the Karolinska Institute, Stockholm (J.U.H.); the Department of Endocrinology, Obesity, and Nutrition, Vestfold Hospital Trust, Tønsberg, and the Department of Endocrinology, Morbid Obesity, and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, Oslo — both in Norway (J.H.); Centro de Investigación en Reumatología y Especialidades Médicas, Bogota, Colombia (P.V.S.); and the University of Toronto and York University, Toronto, McMaster University, Hamil...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-31
- Volume
- 391
- Issue
- 17
- Pages
- 1573-1583
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4403912607
- Cited by
- 440
- References
- 37
- Citations by year
- 2026: 235 · 2025: 197 · 2024: 8
- FWCI
- 141.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Musculoskeletal pain and rehabilitation
- Keywords
- semaglutide, knee osteoarthritis, obesity, GLP-1 receptor agonists, weight loss, osteoarthritis pain, physical function, hypocaloric diet, physical activity counseling, adverse events, serious adverse events, drug safety, quality of life, Western Ontario and McMaster Universities Osteoarthritis Index, SF-36
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Combined Modality Therapy, Counseling, Double-Blind Method, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Obesity, Pain Measurement, Weight Loss, Body Mass Index, Arthralgia, Osteoarthritis, Knee, Caloric Restriction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.